The Clinical Utility of Pharmacogenomics for The Public Health Systems in Developing Countries
Posted 15 March 2013 by Joe Dramiga
Currently, pharmaceutical companies develop and test most drugs in Europe and North America, where they are licensed with efficacy rates as low as 30%. In contrast most drugs are usually marketed worldwide without any idea of how effective or safe they are in different population groups, and certainly without any regard for differences in SNP patterns or of other genomic variation that may correlate to differential drug responses between these groups. ... Read more
Posted in 